Vera Therapeutics (NASDAQ:VERA) Shares Up 3.6%

Vera Therapeutics, Inc. (NASDAQ:VERA) shares were up 3.6% during trading on Friday . The stock traded as high as $35.94 and last traded at $35.90. Approximately 13,510 shares were traded during trading, a decline of 99% from the average daily volume of 1,098,632 shares. The stock had previously closed at $34.66.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on VERA shares. JPMorgan Chase & Co. lifted their price objective on shares of Vera Therapeutics from $60.00 to $65.00 and gave the company an “overweight” rating in a research note on Friday, May 31st. Raymond James increased their price target on Vera Therapeutics from $57.00 to $68.00 and gave the company a “strong-buy” rating in a report on Friday, May 10th. Wedbush raised their target price on shares of Vera Therapeutics from $21.00 to $34.00 and gave the company a “neutral” rating in a research note on Thursday, March 21st. Finally, Guggenheim restated a “buy” rating and set a $56.00 price objective on shares of Vera Therapeutics in a report on Friday, April 5th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $42.86.

Vera Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.14, a quick ratio of 28.63 and a current ratio of 28.63. The company has a market capitalization of $1.98 billion, a P/E ratio of -17.65 and a beta of 1.04. The firm has a 50 day moving average price of $39.05 and a two-hundred day moving average price of $35.46.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). On average, research analysts expect that Vera Therapeutics, Inc. will post -2.34 earnings per share for the current fiscal year.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, SVP Joseph R. Young sold 5,714 shares of the business’s stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $40.00, for a total transaction of $228,560.00. Following the completion of the sale, the senior vice president now directly owns 53,171 shares of the company’s stock, valued at approximately $2,126,840. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, SVP Joseph R. Young sold 5,714 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $40.00, for a total transaction of $228,560.00. Following the transaction, the senior vice president now owns 53,171 shares of the company’s stock, valued at approximately $2,126,840. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sean Grant sold 99,828 shares of Vera Therapeutics stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $39.61, for a total transaction of $3,954,187.08. Following the transaction, the chief financial officer now directly owns 66,337 shares in the company, valued at $2,627,608.57. The disclosure for this sale can be found here. 21.70% of the stock is currently owned by company insiders.

Institutional Trading of Vera Therapeutics

A number of institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. raised its stake in shares of Vera Therapeutics by 20.8% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock worth $172,000 after purchasing an additional 688 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Vera Therapeutics during the 4th quarter worth $79,000. Cetera Advisors LLC bought a new stake in shares of Vera Therapeutics in the first quarter valued at about $235,000. Capstone Investment Advisors LLC acquired a new stake in shares of Vera Therapeutics in the first quarter valued at approximately $248,000. Finally, SG Americas Securities LLC acquired a new stake in Vera Therapeutics during the fourth quarter worth approximately $119,000. 99.21% of the stock is currently owned by institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.